Compare Stocks: CRVS, EWTX, CELC, and ELVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$95.39 -0.8%	$94.65	$44.42 ▼ $151.02	$4.67B	0.19	1.08 million shs	307,552 shs
CRVS Corvus Pharmaceuticals	$14.23 +0.2%	$14.40	$5.60 ▼ $26.95	$1.20B	0.87	2.04 million shs	104,859 shs
ELVN Enliven Therapeutics	$59.46 +0.8%	$55.27	$14.78 ▼ $62.32	$4.36B	0.3	1.23 million shs	401,334 shs
EWTX Edgewise Therapeutics	$41.74 -0.6%	$42.17	$13.69 ▼ $48.40	$4.53B	0.32	1.18 million shs	332,289 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	+4.59%	+1.18%	+9.67%	+4.03%	+79.54%
CRVS Corvus Pharmaceuticals	-0.49%	-3.60%	+6.21%	+21.16%	+150.44%
ELVN Enliven Therapeutics	+1.99%	-3.06%	+1.67%	+66.27%	+182.48%
EWTX Edgewise Therapeutics	-0.64%	-5.41%	+9.38%	+12.76%	+182.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$95.39 -0.8%	$94.65	$44.42 ▼ $151.02	$4.67B	0.19	1.08 million shs	307,552 shs
CRVS Corvus Pharmaceuticals	$14.23 +0.2%	$14.40	$5.60 ▼ $26.95	$1.20B	0.87	2.04 million shs	104,859 shs
ELVN Enliven Therapeutics	$59.46 +0.8%	$55.27	$14.78 ▼ $62.32	$4.36B	0.3	1.23 million shs	401,334 shs
EWTX Edgewise Therapeutics	$41.74 -0.6%	$42.17	$13.69 ▼ $48.40	$4.53B	0.32	1.18 million shs	332,289 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	+4.59%	+1.18%	+9.67%	+4.03%	+79.54%
CRVS Corvus Pharmaceuticals	-0.49%	-3.60%	+6.21%	+21.16%	+150.44%
ELVN Enliven Therapeutics	+1.99%	-3.06%	+1.67%	+66.27%	+182.48%
EWTX Edgewise Therapeutics	-0.64%	-5.41%	+9.38%	+12.76%	+182.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	2.82	Moderate Buy	$154.55	58.42% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	132.48% Upside
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	25.25% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	19.96% Upside

Current Analyst Ratings Breakdown

Latest CRVS, EWTX, CELC, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00
8/17/2026	CELC Celcuity	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$165.00 ➝ $175.00
8/17/2026	CELC Celcuity	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/17/2026	CELC Celcuity	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$177.00
8/14/2026	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00
8/14/2026	CELC Celcuity	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$175.00 ➝ $150.00
8/14/2026	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$157.00 ➝ $140.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	($0.26) per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	112.58	$2.68 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$12.22 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.13 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)

Latest CRVS, EWTX, CELC, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	6.04	8.93	8.93
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
ELVN Enliven Therapeutics	N/A	64.07	64.07
EWTX Edgewise Therapeutics	N/A	16.24	16.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
CRVS Corvus Pharmaceuticals	46.64%
ELVN Enliven Therapeutics	95.08%
EWTX Edgewise Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CELC Celcuity	13.33%
CRVS Corvus Pharmaceuticals	19.70%
ELVN Enliven Therapeutics	3.00%
EWTX Edgewise Therapeutics	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	40	48.93 million	42.41 million	Optionable
CRVS Corvus Pharmaceuticals	30	84.12 million	67.55 million	Optionable
ELVN Enliven Therapeutics	50	73.27 million	71.07 million	Optionable
EWTX Edgewise Therapeutics	60	108.60 million	85.47 million	Optionable

CRVS, EWTX, CELC, and ELVN Headlines

Recent News About These Companies

Braidwell LP Sells 350,618 Shares of Edgewise Therapeutics, Inc. $EWTX

September 3 at 4:39 AM | marketbeat.com

212,347 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Bank of New York Mellon Corp

September 3 at 3:20 AM | marketbeat.com

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 3 at 2:28 AM | americanbankingnews.com

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 3 at 2:28 AM | marketbeat.com

Goldman Sachs Sticks to Their Hold Rating for Edgewise Therapeutics (EWTX)

September 2 at 6:43 PM | theglobeandmail.com

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

September 2 at 8:00 AM | prnewswire.com

Hsbc Holdings PLC Purchases New Shares in Edgewise Therapeutics, Inc. $EWTX

August 30, 2026 | marketbeat.com

Jefferies Financial Group Inc. Purchases Shares of 71,389 Edgewise Therapeutics, Inc. $EWTX

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Acquires New Stake in Edgewise Therapeutics, Inc. $EWTX

August 27, 2026 | marketbeat.com

6,606,336 Shares in Edgewise Therapeutics, Inc. $EWTX Purchased by BlackRock Inc.

August 27, 2026 | marketbeat.com

Artia Global Partners LP Takes Position in Edgewise Therapeutics, Inc. $EWTX

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Edgewise Therapeutics, Inc. $EWTX

August 26, 2026 | marketbeat.com

577,036 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Parkman Healthcare Partners LLC

August 25, 2026 | marketbeat.com

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

August 24, 2026 | prnewswire.com

244,995 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Deutsche Bank AG

August 24, 2026 | marketbeat.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock

August 20, 2026 | marketbeat.com

Edgewise Therapeutics Inc EWTX

August 19, 2026 | morningstar.comM

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

August 18, 2026 | seekingalpha.com

69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd

August 17, 2026 | marketbeat.com

44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP

August 17, 2026 | marketbeat.com

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 2,919 Shares of Stock

August 15, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, EWTX, CELC, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

$95.39 -0.81 (-0.85%)

As of 01:19 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Corvus Pharmaceuticals NASDAQ:CRVS

$14.23 +0.03 (+0.24%)

As of 01:19 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Enliven Therapeutics NASDAQ:ELVN

$59.46 +0.45 (+0.77%)

As of 01:19 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Edgewise Therapeutics NASDAQ:EWTX

$41.74 -0.24 (-0.57%)

As of 01:19 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, EWTX, CELC, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, EWTX, CELC, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, EWTX, CELC, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, EWTX, CELC, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

Enliven Therapeutics NASDAQ:ELVN

Edgewise Therapeutics NASDAQ:EWTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRVS, EWTX, CELC, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRVS, EWTX, CELC, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRVS, EWTX, CELC, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVS, EWTX, CELC, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

Corvus Pharmaceuticals NASDAQ:CRVS

Enliven Therapeutics NASDAQ:ELVN

Edgewise Therapeutics NASDAQ:EWTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools